Mumbai: Pharmaceutical firm Suven Life Sciences Wednesday said the US Patent office has granted product patent to the company for compounds used in the treatment of neuro-degenerative disorders.
Suven informed the Bombay Stock Exchange that it has been granted product patent in the US.
“We are pleased by the issuance of the patent for our drug candidates that are being used in the treatment of Central Nervous System disorders and which target a 18 billion dollar potential market opportunity,” Suven CEO Venkat Jasti said.
This is the second product patent secured by the company in the US. The products are useful in the treatment of neuro-degenerative disorders like Alzheimer’s, Parkinson, Schizophrenia and Huntington’s.
Suven has so far filed 29 product patent applications through Patent Cooperation Treaty covering more than 145 countries and has been granted five product patents, the company said.
Shares of Suven were trading at Rs 40.05, down 4.98 per cent in the afternoon trade on the BSE.